Traders should monitor ramp-up timing toward full capacity and future EMA approval prospects, which could expand market access. The new center strengthens Kamada’s vertical integration and revenue diversification in the high-demand plasma market.
Price Chart
Executive Summary
Kamada Ltd. announced FDA approval of its plasma collection center in San Antonio, Texas, enabling the facility to commence commercial sales of normal source plasma. The center has an annual collection capacity of approximately 50,000 liters and is expected to generate $8 million to $10 million in annual revenue at full capacity, supporting both normal and specialty plasma collection.
Key Facts
- FDA has approved Kamada's plasma collection center in San Antonio, Texas.
- The facility has a planned annual collection capacity of ~50,000 liters of plasma.
- Estimated annual revenue contribution of $8 million to $10 million at full capacity from normal source plasma sales.
- San Antonio center is anticipated to be one of the largest specialty plasma collection centers in the U.S.
- Kamada now owns three FDA-approved plasma collection centers in Texas (Beaumont, Houston, San Antonio).
- Company plans to seek European Medicines Agency (EMA) approval for the San Antonio site.
Financial Impact
Adds $8M to $10M in annual revenue at full capacity, representing a meaningful expansion in Kamada's plasma-derived revenue stream.
Risk Factors
- Revenue projections are forward-looking and dependent on achieving full operational capacity.
- Geopolitical risks in the Middle East may impact operations in Israel.
- Regulatory delays for EMA approval could limit international expansion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-034342 |
| Document: ea0283431-6k_kamada.htm | 0001213900-26-034342 |
| Document: 0001213900-26-034342-index-headers.html | 0001213900-26-034342 |
| Document: 0001213900-26-034342-index.html | 0001213900-26-034342 |
| Document: 0001213900-26-034342.txt | 0001213900-26-034342 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 16, 2026 16d ago | EFFECT | $8.19 $8.77 | ▲ +7.08% | ▲ +4.52% | $8.20 (+0.12%) |
Sep 10, 2026 22d ago | 6-K | $7.99 $8.67 | ▲ +8.51% | ▲ +9.01% | $8.20 (+2.63%) |
Sep 3, 2026 29d ago | Press Release | $8.54 $8.31 | ▼ −2.69% | ▼ −1.48% | $8.20 (−3.98%) |
Sep 3, 2026 29d ago | 6-K | $8.54 $8.31 | ▼ −2.69% | ▼ −1.48% | $8.20 (−3.98%) |
Aug 17, 2026 6w ago | 6-K / PRESS-RELEASE | $7.76 $8.43 | ▲ +8.63% | ▲ +9.82% | $8.20 (+5.67%) |
Aug 12, 2026 7w ago | 6-K | $6.88 $7.89 | ▲ +14.68% | ▲ +15.12% | $8.20 (+19.19%) |
Aug 5, 2026 8w ago | 6-K | $7.14 $7.26 | ▲ +1.68% | ▲ +0.47% | $8.20 (+14.85%) |
Aug 5, 2026 8w ago | 6-K | $7.18 $6.88 | ▼ −4.18% | ▼ −4.53% | $8.20 (+14.21%) |
Jul 20, 2026 10w ago | 6-K | $7.09 $7.06 | ▼ −0.42% | ▲ +0.00% | $8.20 (+15.66%) |
Jul 13, 2026 11w ago | 6-K | $7.17 $7.05 | ▼ −1.67% | ▼ −0.89% | $8.20 (+14.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access